CORCEPT THERAPEUTCS
CORCEPT THERAPEUTCS operates in Diversified Metals & Mining.
CORCEPT THERAPEUTCS (HTD) - Net Assets
Latest net assets as of September 2024: €638.84 Million EUR
Based on the latest financial reports, CORCEPT THERAPEUTCS (HTD) has net assets worth €638.84 Million EUR as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€784.26 Million) and total liabilities (€145.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €638.84 Million |
| % of Total Assets | 81.46% |
| Annual Growth Rate | 43.04% |
| 5-Year Change | 36.51% |
| 10-Year Change | N/A |
| Growth Volatility | 121.58 |
CORCEPT THERAPEUTCS - Net Assets Trend (2016–2023)
This chart illustrates how CORCEPT THERAPEUTCS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CORCEPT THERAPEUTCS (2016–2023)
The table below shows the annual net assets of CORCEPT THERAPEUTCS from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €506.70 Million | +0.97% |
| 2022-12-31 | €501.84 Million | +33.54% |
| 2021-12-31 | €375.81 Million | -28.19% |
| 2020-12-31 | €523.34 Million | +40.99% |
| 2019-12-31 | €371.18 Million | +34.54% |
| 2018-12-31 | €275.88 Million | +44.47% |
| 2017-12-31 | €190.97 Million | +361.51% |
| 2016-12-31 | €41.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CORCEPT THERAPEUTCS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 72479400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €402.53 Million | 79.44% |
| Other Components | €104.18 Million | 20.56% |
| Total Equity | €506.70 Million | 100.00% |
CORCEPT THERAPEUTCS Competitors by Market Cap
The table below lists competitors of CORCEPT THERAPEUTCS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Maxus Realty Trust Inc
PINK:MRTI
|
$655.97K |
|
DIASORIN (34D.SG)
STU:34D
|
$656.12K |
|
Graph Blockchain Inc
PINK:REGRF
|
$656.25K |
|
The LGL Group, Inc. WT
NYSE:LGL-WT
|
$656.29K |
|
CROCS (C7N.SG)
STU:C7N
|
$655.05K |
|
Story-I Ltd
AU:SRY
|
$654.87K |
|
Softimat S.A.
BR:SOFT
|
$654.64K |
|
Bagger Dave's Burger Tavern Inc
PINK:BDVB
|
$654.12K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CORCEPT THERAPEUTCS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 501,842,000 to 506,705,000, a change of 4,863,000 (1.0%).
- Net income of 106,140,000 contributed positively to equity growth.
- Share repurchases of 145,428,000 reduced equity.
- Other factors increased equity by 44,151,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €106.14 Million | +20.95% |
| Share Repurchases | €145.43 Million | -28.7% |
| Other Changes | €44.15 Million | +8.71% |
| Total Change | €- | 0.97% |
Book Value vs Market Value Analysis
This analysis compares CORCEPT THERAPEUTCS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.71x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 40.34x to 13.71x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €1.66 | €67.16 | x |
| 2018-12-31 | €2.40 | €67.16 | x |
| 2019-12-31 | €3.24 | €67.16 | x |
| 2020-12-31 | €4.48 | €67.16 | x |
| 2021-12-31 | €3.55 | €67.16 | x |
| 2022-12-31 | €4.65 | €67.16 | x |
| 2023-12-31 | €4.90 | €67.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CORCEPT THERAPEUTCS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.95%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.00%
- • Asset Turnover: 0.78x
- • Equity Multiplier: 1.23x
- Recent ROE (20.95%) is below the historical average (28.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 19.67% | 10.01% | 1.18x | 1.66x | €4.00 Million |
| 2017 | 67.61% | 81.11% | 0.72x | 1.15x | €110.03 Million |
| 2018 | 27.33% | 30.01% | 0.81x | 1.13x | €47.82 Million |
| 2019 | 25.37% | 30.73% | 0.74x | 1.11x | €57.06 Million |
| 2020 | 20.26% | 29.96% | 0.62x | 1.09x | €53.68 Million |
| 2021 | 29.94% | 30.74% | 0.86x | 1.13x | €74.93 Million |
| 2022 | 20.21% | 25.24% | 0.69x | 1.16x | €51.23 Million |
| 2023 | 20.95% | 22.00% | 0.78x | 1.23x | €55.47 Million |
Industry Comparison
This section compares CORCEPT THERAPEUTCS's net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $114,212,818,724
- Average return on equity (ROE) among peers: -9.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CORCEPT THERAPEUTCS (HTD) | €638.84 Million | 19.67% | 0.23x | $655.25K |
| HORIBA (01H) | $204.49 Billion | 10.42% | 0.82x | $989.01K |
| Tokyu Corporation (01T) | $779.37 Billion | 3.34% | 2.35x | $99.73K |
| GUANGZHOU AUTO -H- (02G) | $122.28 Billion | 6.59% | 0.55x | $4.05K |
| MOSAIC (02M) | $10.60 Billion | 4.43% | 0.90x | $280.83K |
| MOSAIC (02M.SG) (02M) | $9.56 Billion | 10.46% | 0.82x | $247.21K |
| CHINA JO-JO DRGSTRS (04CN.SG) (04CN) | $16.67 Million | -126.83% | 4.46x | $1.55 Million |
| KRAKATAU STEEL -B- (07K) | $552.59 Million | 3.52% | 4.72x | $166.99 |
| CN MODERN DAIRY (07M) | $7.12 Billion | -10.42% | 1.50x | $1.68K |
| TOURMALINE OIL (08T) | $7.22 Billion | 4.81% | 0.41x | $381.02K |
| ASIA CASSAVA RESOUR (0ACS) | $913.15 Million | 2.86% | 1.55x | $325.03 |